Picoplatin

Summary

Picoplatin (CHEMBL3544907) is a phase-3 clinical-stage small molecule; indicated across 11 conditions including small cell lung carcinoma and lung neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 11 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3544907
Name	Picoplatin
Type	Small molecule
Max phase	3

Also known as: AMD-473, AMD473, NX 473, NX-473, NX473, Picoplatin, Picoplatine, Picoplatino, ZD-0473, ZD0473, PICOPLATIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
small cell lung carcinoma	3	MONDO:0008433	EFO:0000702
lung neoplasm	2	MONDO:0021117	MONDO:0008903
neoplasm	1	MONDO:0005070	EFO:0000616
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
head and neck cancer	1	MONDO:0005627	EFO:0006859
breast neoplasm	1	MONDO:0021100	MONDO:0007254
ovarian cancer	1	MONDO:0008170	MONDO:0008170
digestive system neoplasm	1	MONDO:0021223	EFO:0008549
colorectal neoplasm	1	MONDO:0005335	MONDO:0005575

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE1	3
PHASE2	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00465491	PHASE3	UNKNOWN	Study of Picoplatin Efficacy After Relapse
NCT00021008	PHASE2	UNKNOWN	ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer
NCT00116610	PHASE2	COMPLETED	Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer
NCT00448734	PHASE1/PHASE2	UNKNOWN	A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer
NCT00016172	PHASE1	COMPLETED	ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00465725	PHASE1	COMPLETED	A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
NCT00710697	PHASE1	UNKNOWN	Cardiac Safety Assessment Study of Picoplatin in Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).